/ /

  • linkedin
  • Increase Font
  • Sharebar

    Neuroprotective treatment promising for macular telangiectasia

    CNTF found effective in slowing vision loss from photoreceptor cell death in animal models


    More about the disease

    A degenerative condition of the macula, macular telangiectasia type 2 affects both eyes and may cause progressive loss of central vision. It afflicts about one person in 22,000.

    The condition was described in 1982, and until recently, physicians knew little about it.

    “It’s often misdiagnosed as macular degeneration,” Dr. Friedlander said.

    Macular telangiectasia is classified as three types, but the diseases are not related.

    In type 2, the most common type, leakage occurs during fluorescein angiography with manifest retinal capillary dilatation but without retinal thickening. Patients are typically diagnosed in their 40s or 50s. As the disease progresses, intraretinal pigment plaques and intraretinal or subretinal neovascularization may develop.

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results